Abstract |
We previously reported that gp43 tumor-associated antigen peptide (DLTMKYQIF; designated 810 antigen) on human melanoma cells is recognized by IgM human monoclonal antibody L92 and by cytotoxic T lymphocytes (CTL). In this study, we retrospectively tested sera of 44 patients with regional metastatic melanoma (22 who recurred within 1 year and 22 who survived longer than 5 years) to determine if antibody responses to 810 antigen could be induced by immunization with an allogeneic melanoma cell vaccine that contained 810 peptide. IgM and IgG antibodies were assessed by enzyme-linked immunosorbent assay using a synthetic 810 nonamer peptide. A significant augmentation of IgM antibody was demonstrated 4 weeks after initiation of vaccine therapy, and the IgM level was significantly higher in patients who survived more than 5 years. The antigen epitope recognized by antibodies was located within TMKYQI. Of this epitope sequence, K appears to play a central role in antigenicity. The 810 antigen recognized by antibody and CTL may have clinical relevance as a potential source of melanoma vaccine.
|
Authors | T Takahashi, A Conforti, Y Kikumoto, D S Hoon, D L Morton, R F Irie |
Journal | Journal of clinical immunology
(J Clin Immunol)
Vol. 18
Issue 4
Pg. 299-305
(Jul 1998)
ISSN: 0271-9142 [Print] Netherlands |
PMID | 9710747
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antibodies, Neoplasm
- Antigens, Neoplasm
- Immunoglobulin M
- Neoplasm Proteins
- Peptides
- tumor-associated antigen, gp43
|
Topics |
- Antibodies, Neoplasm
(biosynthesis, blood)
- Antigens, Neoplasm
(immunology)
- Humans
- Immunoglobulin M
(biosynthesis, blood)
- Melanoma
(immunology, therapy)
- Neoplasm Metastasis
(immunology)
- Neoplasm Proteins
(immunology)
- Peptides
(chemical synthesis, immunology)
- Prognosis
- Retrospective Studies
- Skin Neoplasms
(immunology, therapy)
- T-Lymphocytes, Cytotoxic
(immunology)
- Vaccination
|